Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

por Janssen, Yester F., Feitsma, Eline A., Boersma, Hendrikus H., Alleva, David G., Lancaster, Thomas M., Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Delpero, Andrea R., Scully, Melanie M., Ragupathy, Ramya, Kotha, Sravya, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Ronca, Shannon E., Green, Freedom M., Aminetzah, Ari, Sollie, Frans, Kruijff, Schelto, Brom, Maarten, van Dam, Gooitzen M., Zion, Todd C.
Publicado 2022

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

por Feitsma, Eline A., Janssen, Yester F., Boersma, Hendrikus H., van Sleen, Yannick, van Baarle, Debbie, Alleva, David G., Lancaster, Thomas M., Sathiyaseelan, Thillainaygam, Murikipudi, Sylaja, Delpero, Andrea R., Scully, Melanie M., Ragupathy, Ramya, Kotha, Sravya, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Ronca, Shannon E., Green, Freedom M., Aminetzah, Ari, Sollie, Frans, Kruijff, Schelto, Brom, Maarten, van Dam, Gooitzen M., Zion, Todd C.
Publicado 2023